« Previous
Next »
Titles
- Tezepelumab for severe asthma: final report2
- AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report1
- Aducanumab for Alzheimer’s disease: effectiveness and value1
- Alirocumab for treatment of high cholesterol: effectiveness and value : new evidence update1
- Alternative policies for pricing novel vaccines and drug therapies for COVID-191
- Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report1
- Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report1
- Betibeglogene autotemcel for beta thalassemia: effectiveness and value : final evidence report1
- CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report1
- Controversies in migraine management: a technology assessment : final report1
- Controversies in obesity management: a technology assessment : final report1
- Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value1
- Diagnostic tests for Alzheimer's disease: generating and evaluating evidence to inform insurance coverage policy1
- Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary1
- Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report1
- Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report1
- Gene therapies for sickle cell disease: final evidence report1
- Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report1